It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

pharmaceuticals

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Biogen stung as U.S. limits coverage of Alzheimer’s therapy

World / Science & Health Jan 12, 2022

Biogen stung as U.S. limits coverage of Alzheimer’s therapy

by John Tozzi, Angelica Peebles and Robert Langreth

Private insurers in the U.S. have mostly declined to cover Aduhelm, saying they need more proof of its efficacy and that benefits outweigh risks like brain swelling.

Singapore breaks down COVID-19 deaths by vaccine, with Moderna seeing lowest rate

World / Science & Health Jan 11, 2022

Singapore breaks down COVID-19 deaths by vaccine, with Moderna seeing lowest rate

by Low De Wei

While there were some caveats, the findings will likely add to concerns around the efficacy of Sinovac’s and Sinopharm Group’s shots, which have been widely used in the developing world.

Pfizer starts making vaccine that targets both omicron and the original COVID virus

World / Science & Health Jan 11, 2022

Pfizer starts making vaccine that targets both omicron and the original COVID virus

by Riley Griffin

While research continues, Pfizer will evaluate the new hybrid shot against one specific to omicron and determine which should move forward by March, the firm's CEO has said.

Tardy COVID-19 vaccine makers under fire for trials in developing nations

Business Dec 27, 2021

Tardy COVID-19 vaccine makers under fire for trials in developing nations

by Kanoko Matsuyama

Vaccine developers at the testing phase now are seeking developing countries where vaccination rates remain low and the virus is still active.

Japan government panel approves first oral COVID-19 pill

National / Science & Health Dec 24, 2021

Japan government panel approves first oral COVID-19 pill

Clinical trial data shows that patients given the pill within five days of developing symptoms were 30% less likely to be hospitalized or die.

Pfizer pill adds to growing U.S. stockpile of COVID-19 treatments

World Dec 23, 2021

Pfizer pill adds to growing U.S. stockpile of COVID-19 treatments

by Josh Wingrove

Infections are rising across the country, but the treatments will give doctors a larger arsenal with which to fight severe coronavirus cases.

Ivermectin for COVID? Unproven treatment stokes concern in Japan

National | FOCUS Dec 21, 2021

Ivermectin for COVID? Unproven treatment stokes concern in Japan

by Osamu Tsukimori

Although the treatment has received some support from Japan's medical establishment and studies are ongoing, ivermectin is not approved as a COVID-19 remedy in the country.

Moderna says its booster dose appears protective against omicron

World / Science & Health Dec 20, 2021

Moderna says its booster dose appears protective against omicron

The data, which has not yet been peer reviewed, tested blood from people who had received the vaccine against a pseudovirus engineered to resemble the omicron variant.

Japan to shorten booster shot interval for medical workers and seniors on omicron concerns

National Dec 18, 2021

Japan to shorten booster shot interval for medical workers and seniors on omicron concerns

by Kazuaki Nagata

The interval between second shots and booster shots will be six months for health care workers and those living in nursing homes, the prime minister said.

Six vaccines show promise as boosters, led by mRNA shots

World / Science & Health Dec 3, 2021

Six vaccines show promise as boosters, led by mRNA shots

by Suzi Ring and Irina Anghel

Researchers tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the AstraZeneca or Pfizer shots.

Japanese drugmaker Shionogi considers developing vaccine for omicron variant

National / Science & Health Nov 30, 2021

Japanese drugmaker Shionogi considers developing vaccine for omicron variant

The company is currently conducting a final clinical trial of its COVID-19 vaccine, aiming to make it available in March.

SoftBank’s Masayoshi Son bets on narcolepsy drug for sleep-deprived Japan

Business / Corporate Nov 25, 2021

SoftBank’s Masayoshi Son bets on narcolepsy drug for sleep-deprived Japan

by Kanoko Matsuyama and Takahiko Hyuga

The proportion of people sleeping less than the recommended eight hours is rising globally, and costs Japan as much as $138 billion in economic losses each year, according to Rand Corp.

« 1 … 9 10 11 … 42 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times